CoChat

Gender medicine and oncology: report and consensus of an ESMO workshop

Open access
Wagner, A.D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., Fellay, J., Haanen, J., Hocquelet, A., Klinge, I., Lemmens, V., Letsch, A., Mauer, M., Moehler, M., Peters, S., Özdemir, B.C. · 2019 · Annals of Oncology
Cited by 214

The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.

Abstract

BACKGROUND The importance of sex and gender as modulators of disease biology and treatment outcomes is well known in other disciplines of medicine, such as cardiology, but remains an undervalued issue in oncology. Considering the increasing evidence for their relevance, ESMO decided to address this topic and organized a multidisciplinary workshop in Lausanne, Switzerland, on November 30th and December 1st, 2018. DESIGN 20 invited faculty members and 40 selected physicians/scientists participated. Relevant content was presented by faculty members on the basis of a literature review conducted by each speaker. Following a moderated consensus session, the final consensus statements are reported here. RESULTS Clinically relevant sex differences include tumor biology, immune system activity, body composition and drug disposition and effects. The main differences between male and female cells are sex chromosomes and the level of sexual hormones they are exposed to. They influence both local and systemic determinants of carcinogenesis. Their effect on carcinogenesis in non-reproductive organs is largely unknown. Recent evidence also suggests differences in tumor biology and molecular markers. Regarding body composition, the difference in metabolically active, fat-free body mass is one of the most prominent: in a man and a woman of equal weight and height, it accounts for 80% of the man's and 65% of the woman's body mass, and is not taken into account in body-surface area based dosing of chemotherapy. CONCLUSION Sex differences in cancer biology and treatment deserve more attention and systematic investigation. Interventional clinical trials evaluating sex-specific dosing regimens are necessary to improve the balance between efficacy and toxicity for drugs with significant pharmacokinetic differences. Especially in diseases or disease subgroups with significant differences in epidemiology or outcomes, men and women with non-sex related cancers should be considered as biologically distinct groups of patients, for whom specific treatment approaches merit consideration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/annonc/mdz414

Cites

17 of 17 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 17 references

Cited by

See all 214

Metadata

Authors
Wagner, A. D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., Fellay, J., Haanen, J., Hocquelet, A., Klinge, I., Lemmens, V., Letsch, A., Mauer, M., Moehler, M., Peters, S., & Özdemir, B. C.
Venue
Annals of Oncology
Publisher
Elsevier BV
Published
2019-12
Volume
30
Issue
12
Pages
1914-1924
ISSN
0923-7534 (ISSN-L)
OpenAlex
W2980659545
Cited by
214
References
17
FWCI
18.30
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gender medicine and oncology: report and consensus of an ESMO workshop. https://app.cochat.ai/papers/10.1093/annonc/mdz414
The paper
Wagner, A. D., Oertelt-Prigione, S., Adjei, A., Buclin, T., Cristina, V., Csajka, C., Coukos, G., Dafni, U., Dotto, G.-P., Ducreux, M., Fellay, J., Haanen, J., Hocquelet, A., Klinge, I., Lemmens, V., Letsch, A., Mauer, M., Moehler, M., Peters, S., & Özdemir, B. C. (2019). Gender medicine and oncology: report and consensus of an ESMO workshop. Annals of Oncology. https://doi.org/10.1093/annonc/mdz414

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.